Biogen (BIIB) to Invest $2 Billion in U.S. Expansion Amid Onshoring Push

Biogen Inc. (NASDAQ:BIIB) ranks among the stocks to benefit from an onshoring boom. On July 21, Biogen Inc. (NASDAQ:BIIB) declared that it would invest $2 billion to its existing North Carolina production facilities as part of its efforts to grow in the United States in the face of tariff threats from President Donald Trump.

Although President Trump has frequently maintained that separate levies are necessary to support American manufacturing and prevent reliance on other nations for medical supplies, drugs have so far been spared from his reciprocal tariffs.

According to the company, the investments will increase Biogen’s capacity to develop and produce specific gene-targeting treatments, as well as add fill-finish facilities, automation, and artificial intelligence. Biogen Inc. (NASDAQ:BIIB) has so far invested around $10 billion in its North Carolina production.

Biogen Inc. (NASDAQ:BIIB) is a multinational biopharmaceutical company dedicated to discovering, developing, and providing innovative treatments to patients with severe complex illnesses.

While we acknowledge the potential of BIIB as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

Read More: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds

Disclosure: None.